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CASE REPORT
Increased Vascular-Endothelial Growth Factor (VEGF)
Tumor Expression and Response to Epidermal Growth
Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small
Cell Lung Cancer (NSCLC)
Wolfgang M. Brueckl, MD,* Anja Schoeberl, MD,* Ralph M. Wirtz, PhD,† Samuel Murray, PhD,‡
Eckhart G. Hahn, MD, MME, FACP,* and Gunther H. Wiest, MD*
A 37-year-old female never smoker with metastatic large cell car-
cinoma of the lung had a partial response to a second line palliative
therapy with the EGF-R tyrosine kinase inhibitor erlotinib after
platinum based first line therapy failed. Molecular analysis of the
primary and a liver metastasis did neither find any EGF-R mutation
nor an EGF-R amplification. However, both the primary and the
metastasis showed an increased gene expression of vascular-endo-
thelial growth factor-A in contrast to normal tissue, which was
confirmed by immunohistochemistry. To our knowledge, this is the
first report about a high vascular-endothelial growth factor-A ex-
pression in the tumor of a patient responding to an EGF-R inhibitor
postulating that there might be a link between both tyrosine kinase
pathways.
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(J Thorac Oncol. 2008;3: 314–316)
A 37-year-old Caucasian woman presenting with a6-month history of coughing with hemoptysis and a
weight loss of 5 kg in 6 months was admitted to our hospital
on October 3, 2005. The patient has never smoked. In the
flexible bronchoscopy the left segmental ostium 9 was closed.
Snap biopsies of this region revealed a low-grade large cell
NSCLC. Furthermore, a centigram of the bones suspected
bone metastases at the left iliac spine, confirmed by an MRT
of the pelvis. The investigations were completed by CT scans
of the thorax and abdomen, which resulted in an UICC IV
tumor stage.
The patient was given palliative first line chemother-
apy, consisting of carboplatin 300 mg/m2 and docetaxel 75
mg/m2 on days 1 and 22. On staging CT scans progressive
disease was evident with an increased primary tumor (Figure
1A; arrows) with increased and additional metastases in the
liver (Figure 1C). Additionally, brain metastases were present
on cranial CT. Cranial irradiation with a total dose of 50 Gy
was applied, beginning on December 8. As the performance
status was still acceptable (EGOG-PS 2), a palliative second
line oral therapy with the EGF-R tyrosine kinase inhibitor
erlotinib (150 mg/d) was started on December 14, 2005. On
February 10, 2006, a further tumor staging showed a partial
remission of both the primary tumor and at all metastatic
sites. Brain metastasis was no longer evident. On April 11,
2006 (4 months erlotinib), staging with CT scans confirmed
the partial response (Figure 1B, D). About 10 months after the
initial diagnosis of metastatic NSCLC, the patient died with
progressive kachexia and dyspnoea due to recurrent pulmonal
bleeding on July 1, 2006. Formalin fixed paraffin embedded
tissue from biopsies of primary tumor and the liver metastasis
taken during initial diagnosis, was laser microdissected. DNA
and RNA were isolated separately from the tumor cells and
normal epithelial tissue, respectively. Exons 18 to 21 of the
EGF-R gene were bidirectionally sequenced and no somatic
mutation could be detected neither in the primary nor in the
liver metastasis (data not shown).1 Chromogenic in situ
hybridization analysis showed only a low polysomy of the
EGF-R according to the categories defined by Cappuzzo et
al.2 (Figure 2A; original magnification 500). Additionally,
using tumor RNA, gene expression analysis on the EGF-R
gene and further members of the epidermal growth factor
receptor family genes (Her2/neu, ERBB3, ERBB4) together
with four housekeeping genes was performed by RT-PCR.
Additionally, as there were hints from metastatic colorectal
carcinoma, that there might be interactions between the
EGF-R and the vascular-endothelial growth factor (VEGF)
ligands,3 the VEGF family gene expressions (VEGF-A,
VEGF-B, VEGF-C, and VEGF-D) where exploited by this
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method, too. Although there was an evident over expression
of EGF-R gene in the primary tumor (lower were detected in
the liver metastasis), VEGF-A gene was greatly up-regulated
in the primary (P) and in the liver metastases (M) in contrast
to normal lung epithelial cells (N) (Figure 2B). The level of
expression of the other genes did not differ significantly between
normal and tumor tissue(s). The VEGF-A over expression was
confirmed on the protein level by immunohistochemistry. With
antibodies against VEGF-A (Santa Cruz, CA, at 1:120 dilution)
there was a strong cytoplasmatic staining as well in the primary
lung tumor (Figure 2C) as in the liver metastasis (Figure 2C, D;
original magnification 50).
DISCUSSION
Angiogenesis has been demonstrated to be an important
event in the process of tumor growth and metastatic dissem-
FIGURE 1. Radiological images
before and after erlotinib treatment
Axial, contrast-enhanced, CT images
of the lungs show (A) the primary
tumor (arrays) in the left lower lobe
(December 2005), (B) which shrunk
after treatment (April 2006). Addi-
tionally, coronal contrastenhanced
CT images of the abdomen, (C) pre-
senting with multiple liver metasta-
ses (December 2005), (D) which sig-
nificantly decreased in size and
number after therapy (April 2006).
FIGURE 2. Expression analysis of
EGF-R and VEGF in the tumor and
liver metastasis (A) Chromogenic in
situ hybridisation (CISH) analysis
showing low polysomy (array) of the
EGF-R locus in the nuclei of the tu-
mor cells. (B) Results from the ex-
pression analysis of the EGF-R and
VEGF genes by quantitative real-time
polymerase chain-reaction (qRT-PCR)
after laser microdissection in normal
lung epithelium (N), primary tumor
(P) and liver metastasis (M) present-
ing a high VEGF overexpression in
both the tumor and the metastasis.
The VEGF oxerexpression could be
confirmed with immunohistochemis-
try, (C) showing a strong cytoplas-
matic staining (dark red) of both the
primary lung tumor cells and (D) the
liver metastasis using anti-VEGF anti-
bodies.
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ination. In this context, VEGF is a well-established key
regulator of new blood vessel formation. To our knowledge,
there is no report published so far about a clinical response of
a VEGF over expressing NSCLC to an EGF-R therapy. The
question arises, whether VEGF is of predictive relevance in
this context. Data from head and neck squamous cell carci-
noma cell lines, where EGF-R inhibitors lead to down-
regulation of VEGF-A expression casually support our ob-
servations.4 Furthermore, in metastatic CRC a sudden and
long lasting reduction of VEGF serum levels was seen during
palliative therapy with cetuximab, an anti-EGF-R antibody.3
To date, the mechanism(s) leading to VEGF down-regulation
have not been fully explained. It is hypothesized, that VEGF
expression might be either down-regulated by hypoxia induc-
ible factor 1 , a transcriptional regulator of VEGF expres-
sion and/or via the Sp1 binding site of the VEGF promoter.4,5
Our hypothesis has some limitations. Firstly, we do not know
whether VEGF over expression was still evident at the
beginning of the second-line EGF-R therapy, while the bi-
opsy was taken at the time of diagnosis. Secondly, we do not
know, whether there was a down-regulation of VEGF in the
tumor, as we did not have a biopsy at the time of best
response. Thirdly, there is currently some debate concerning
the sensitivity and specificity of molecular techniques to
identify somatic mutations within the tyrosine kinase domain
of the EGF-R gene. As every mutation screening method,
direct bidirectional sequencing as used herein, has its limita-
tions. However, this method is well established and to date
there is no clear comparison available to indicate the overall
failure rate of any given technology.1,6,7 We conclude, that
EGF-R therapy might have influence on clinical response by
down-regulation of VEGF-A. However, the specific role of
VEGF in NSCLC and its importance for treatment decisions
remains to be investigated. A retrospective analysis of
VEGF-A in tumors of patients responding to erlotinib has
been started by our group.
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